Fluad + Saline
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Safety Markers of Adjuvanted Influenza Vaccine
Conditions
Safety Markers of Adjuvanted Influenza Vaccine
Trial Timeline
Oct 2, 2014 → Aug 1, 2016
NCT ID
NCT02523287About Fluad + Saline
Fluad + Saline is a approved stage product being developed by Novartis for Safety Markers of Adjuvanted Influenza Vaccine. The current trial status is completed. This product is registered under clinical trial identifier NCT02523287. Target conditions include Safety Markers of Adjuvanted Influenza Vaccine.
What happened to similar drugs?
2 of 3 similar drugs in Safety Markers of Adjuvanted Influenza Vaccine were approved
Approved (2) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02523287 | Approved | Completed |
Competing Products
20 competing products in Safety Markers of Adjuvanted Influenza Vaccine